Literature DB >> 19721013

Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.

Thomas V Adamkiewicz1, Miguel R Abboud, Carole Paley, Nancy Olivieri, Melanie Kirby-Allen, Elliott Vichinsky, James F Casella, Ofelia A Alvarez, Julio C Barredo, Margaret T Lee, Rathi V Iyer, Abdullah Kutlar, Kathleen M McKie, Virgil McKie, Nadine Odo, Beatrice Gee, Janet L Kwiatkowski, Gerald M Woods, Thomas Coates, Winfred Wang, Robert J Adams.   

Abstract

Chronic blood transfusion is increasingly indicated in patients with sickle cell disease. Measuring resulting iron overload remains a challenge. Children without viral hepatitis enrolled in 2 trials for stroke prevention were examined for iron overload (STOP and STOP2; n = 271). Most received desferrioxamine chelation. Serum ferritin (SF) changes appeared nonlinear compared with prechelation estimated transfusion iron load (TIL) or with liver iron concentrations (LICs). Averaged correlation coefficient between SF and TIL (patients/observations, 26 of 164) was r = 0.70; between SF and LIC (patients/observations, 33 of 47) was r = 0.55. In mixed models, SF was associated with LIC (P = .006), alanine transaminase (P = .025), and weight (P = .026). Most patients with SF between 750 and 1500 ng/mL had a TIL between 25 and 100 mg/kg (72.8% +/- 5.9%; patients/observations, 24 of 50) or an LIC between 2.5 and 10 mg/g dry liver weight (75% +/- 0%; patients/observations, 8 of 9). Most patients with SF of 3000 ng/mL or greater had a TIL of 100 mg/kg or greater (95.3% +/- 6.7%; patients/observations, 7 of 16) or an LIC of 10 mg/g dry liver weight or greater (87.7% +/- 4.3%; patients/observations, 11 of 18). Although SF changes are nonlinear, levels less than 1500 ng/mL indicated mostly acceptable iron overload; levels of 3000 ng/mL or greater were specific for significant iron overload and were associated with liver injury. However, to determine accurately iron overload in patients with intermediately elevated SF levels, other methods are required. These trials are registered at www.clinicaltrials.gov as #NCT00000592 and #NCT00006182.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19721013      PMCID: PMC2780299          DOI: 10.1182/blood-2009-02-203323

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  Immunochemical characterization of human liver and heart ferritins with monoclonal antibodies.

Authors:  A Luzzago; P Arosio; C Iacobello; G Ruggeri; L Capucci; E Brocchi; F De Simone; D Gamba; E Gabri; S Levi
Journal:  Biochim Biophys Acta       Date:  1986-07-25

Review 2.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

Review 3.  Iron-chelating therapy and the treatment of thalassemia.

Authors:  N F Olivieri; G M Brittenham
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

4.  Essential and toxic element concentrations in fresh and formalin-fixed human autopsy tissues.

Authors:  V J Bush; T P Moyer; K P Batts; J E Parisi
Journal:  Clin Chem       Date:  1995-02       Impact factor: 8.327

5.  Survival in medically treated patients with homozygous beta-thalassemia.

Authors:  N F Olivieri; D G Nathan; J H MacMillan; A S Wayne; P P Liu; A McGee; M Martin; G Koren; A R Cohen
Journal:  N Engl J Med       Date:  1994-09-01       Impact factor: 91.245

6.  Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major.

Authors:  G M Brittenham; A R Cohen; C E McLaren; M B Martin; P M Griffith; A W Nienhuis; N S Young; C J Allen; D E Farrell; J W Harris
Journal:  Am J Hematol       Date:  1993-01       Impact factor: 10.047

7.  Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.

Authors:  P Mazza; R Giua; S De Marco; M G Bonetti; B Amurri; C Masi; G Lazzari; C Rizzo; M Cervellera; A Peluso
Journal:  Haematologica       Date:  1995 Sep-Oct       Impact factor: 9.941

8.  Serum ferritin concentration in sickle cell crisis.

Authors:  A Brownell; S Lowson; M Brozović
Journal:  J Clin Pathol       Date:  1986-03       Impact factor: 3.411

9.  Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease.

Authors:  H C Kim; N P Dugan; J H Silber; M B Martin; E Schwartz; K Ohene-Frempong; A R Cohen
Journal:  Blood       Date:  1994-02-15       Impact factor: 22.113

10.  Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.

Authors:  M A Aldouri; B Wonke; A V Hoffbrand; D M Flynn; M Laulicht; L A Fenton; P J Scheuer; C C Kibbler; C A Allwood; D Brown
Journal:  J Clin Pathol       Date:  1987-11       Impact factor: 3.411

View more
  36 in total

1.  Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II.

Authors:  Miguel R Abboud; Eunsil Yim; Khaled M Musallam; Robert J Adams
Journal:  Blood       Date:  2011-06-01       Impact factor: 22.113

2.  Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors.

Authors:  Adisak Tantiworawit; Pimlak Charoenkwan; Sasinee Hantrakool; Worawut Choeyprasert; Chate Sivasomboon; Torpong Sanguansermsri
Journal:  Int J Hematol       Date:  2016-04-06       Impact factor: 2.490

3.  Noninvasive measurement of liver iron concentration at MRI in children with acute leukemia: initial results.

Authors:  Tibor Vag; Karim Kentouche; Ines Krumbein; Jürgen R Reichenbach; Eric Lopatta; Diane M Renz; Martin Stenzel; James Beck; Werner A Kaiser; Hans-Joachim Mentzel
Journal:  Pediatr Radiol       Date:  2011-06-15

4.  Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease.

Authors:  Henrietta Enninful-Eghan; Reneé H Moore; Rebecca Ichord; Kim Smith-Whitley; Janet L Kwiatkowski
Journal:  J Pediatr       Date:  2010-09       Impact factor: 4.406

5.  Interim assessment of liver damage in patients with sickle cell disease using new non-invasive techniques.

Authors:  Emma Drasar; Emer Fitzpatrick; Kate Gardner; Moji Awogbade; Anil Dhawan; Adrian Bomford; Abid Suddle; Swee L Thein
Journal:  Br J Haematol       Date:  2016-12-16       Impact factor: 6.998

Review 6.  Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Winfred C Wang
Journal:  Cochrane Database Syst Rev       Date:  2017-01-17

7.  Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload.

Authors:  Bérengère Koehl; Florence Missud; Laurent Holvoet; Ghislaine Ithier; Oliver Sakalian-Black; Zinedine Haouari; Emmanuelle Lesprit; André Baruchel; Malika Benkerrou
Journal:  J Vis Exp       Date:  2017-03-14       Impact factor: 1.355

Review 8.  Quantification of liver iron with MRI: state of the art and remaining challenges.

Authors:  Diego Hernando; Yakir S Levin; Claude B Sirlin; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2014-03-03       Impact factor: 4.813

9.  Iron overload in sickle cell disease.

Authors:  Radha Raghupathy; Deepa Manwani; Jane A Little
Journal:  Adv Hematol       Date:  2010-05-17

10.  Trends in blood transfusion among hospitalized children with sickle cell disease.

Authors:  Jean L Raphael; Suzette O Oyeku; Marc A Kowalkowski; Brigitta U Mueller; Angela M Ellison
Journal:  Pediatr Blood Cancer       Date:  2013-06-18       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.